KRAS and neoplasm: It has been confirmed that the presence of tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival (4, 5), and the success of TILs in one patient with KRAS G12D mutation indicates the promise of adaptive immunotherapy in CRC patients (6).